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Abstract: Atrial fibrillation (AF) is associated with substantially increased risk of cardiovascular
events and overall mortality. The Atrial fibrillation Better Care (A—Avoid stroke, B—Better symptom
management, C—Cardiovascular and comorbidity risk management) pathway provides a simple
and comprehensive approach for integrated AF therapy. This study’s goals were to evaluate the
ABC pathway compliance and determine the main gaps in AF management in the Middle East
population, and to assess the impact of ABC pathway adherence on the all-cause mortality and
composite outcome in AF patients. 2021 patients (mean age 57; 52% male) from the Gulf SAFE registry
were studied. We evaluated: A—appropriate implementation of OACs according to CHA2DS2-VASc
score; B—symptom control according to European Heart Rhythm Association (EHRA) symptom scale;
C—proper cardiovascular comorbidities management. The primary endpoints were the composite
cardiovascular outcome (ischemic stroke or systemic embolism, all-cause death and cardiovascular
hospitalization) and all-cause mortality. One-hundred and sixty-eight (8.3%) patients were optimally
managed according to adherence with the ABC pathway. Over the one-year follow up (FU), there
were 578 composite outcome events and 224 deaths. Patients managed with integrated care had
significantly lower rates for the composite outcome and mortality comparing to non-ABC group
(20.8% vs. 29.3%, p = 0.02 and 7.3% vs. 13.1%, p = 0.033, respectively). On multivariable analysis,
ABC compliance was independently associated with reduced risk of composite outcome (HR 0.53;
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95% CI 0.36–0.8, p = 0.002) and death (HR 0.46; 95% CI 0.25–0.86, p = 0.015). Integrated ABC pathway
adherent care resulted in the reduced composite outcome and all-cause mortality in AF patients from
Middle East, highlighting the necessity of promoting comprehensive holistic and integrated care
management of AF.
Keywords: atrial fibrillation; mortality; ABC pathway
1. Introduction
Atrial fibrillation (AF) is the most frequent cardiac arrhythmia in clinical practice and it is
influenced by various underlying risk factors [1,2]. Substantial cardiovascular morbidity and mortality
result from AF and AF-related complications [3]. Additionally, AF is the leading cause of disability
and impaired quality of life by rising the number of hospitalizations and exacerbating other disease
entities such as heart failure, stroke and dementia [4,5]. Of note, AF-related strokes are associated with
more disabling or fatal complications than strokes resulting from non-AF aetiologies [6].
Over the last decades, the attitude to stroke prevention in AF has changed, with various available
therapeutic options as well as validated scores and schemes for bleeding and stroke risk assessment [6,7].
As stroke prevention is the cornerstone of AF management, a comprehensive knowledge of AF risk
factors and their inter-relationships are of the utmost importance. In addition, the dynamic nature of
these risk factors has recently been highlighted [2].
The Atrial fibrillation Better Care (ABC) pathway for integrated care management presents a
novel approach to streamline the holistic management of AF [4]. The ABC pathway provides a simple
strategy for a comprehensive treatment including improvement in detection and awareness of AF, as
well as dealing with AF symptoms and managing risk factors (Figure S1). Given that stroke prevention
is a pivotal part of AF therapy, oral anticoagulation (OAC) is recommended for all patients, except
those at low risk who are unlikely to benefit from this treatment [8,9]. ‘B’ refers to better symptom
control, so effective treatment of AF symptoms concerning individualized rate and rhythm control
management. ‘C’ applies to the management of comorbidities and cardiovascular risk factors [4].
Previous retrospective studies have showed the association between ABC pathway adherence and
lower risk of clinical outcomes as well as decrease in health-related costs [10–12].
For the first time in the Middle East region, this study evaluated if AF management that is
compliant or adherent with the ABC pathway was associated with improved clinical outcomes. These
clinical outcomes include reducing all-cause mortality and the composite outcome of ischemic stroke
or systemic embolism, all-cause death and cardiovascular hospitalization.
2. Materials and Methods
This was a retrospective post-hoc analysis from the Gulf Survey of Atrial Fibrillation Events
(SAFE) registry dataset, which is an international, prospective, observational register of AF patients
from six countries in the Gulf region of the Middle East. Detailed information on the methods has
been previously published [13]. In brief, the Gulf SAFE registry was based on consecutive AF patients
admitted to emergency departments from 23 participating hospitals carried out between 15 October
2009, and 30 June 2010, independently from the primary reason for admission. Patients older than
18 years qualified for inclusion if they had >30 s AF on a 12-lead resting electrocardiogram. All patients
were informed about the details of the study and gave informed consent for their participation.
The study was approved by the ethics committees of each institution/country.
The Gulf SAFE registry enrolled 2043 patients with AF. For the purpose of the study, we included
2021 in further analysis, omitting those with missing data about the CHA2DS2-VASc score.
We analysed compliance with the ABC pathway components, which were defined as follows on
the basis of ESC Guidelines [8] (see Supplementary Materials Figure S2 available online):
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• ‘A’—‘Avoid stroke’—we identified patients at low risk of ischemic stroke (those with a
CHA2DS2-VASc score of 0 in men or 1 in women) and assess whether everyone else is treated
with OAC. (‘A compliant’). Patients at high risk of stroke, who did not receive OAC and those
with low risk of stroke, but unnecessarily anticoagulated were considered as ‘A non-compliant’.
The vast majority of patients receiving OAC in the current study were administered with vitamin
K antagonists (VKA, e.g., warfarin).
• ‘B—better symptoms control’—we evaluated the occurrence of symptoms and classified them
according to the European Heart Rhythm Association (EHRA) symptom scale. We assumed that
patients with EHRA I or II had good control of AF symptoms (‘B complaint’) in comparison to
those with EHRA III or IV, who were treated insufficiently (‘B non-complaint’).
• ‘C—Cardiovascular risk and other comorbidity optimisation’—To reduce cardiovascular risk,
we evaluated appropriate treatment of the following comorbidities based on available data:
hypertension (HT), coronary artery disease (CAD), peripheral artery disease (PAD) and ischemic
stroke/TIA. HT assessment was based on an average of the blood pressure values at hospital
admission that should be < 140/90 mmHg in order to be considered as well controlled. For
other comorbidities, optimal pharmacologic management was evaluated in accordance with the
current European guidelines and recommendations. (Figure S2). ‘C compliant’ means that all
comorbidities were either well-controlled or treated with appropriate prevention drugs or both.
Finally, patients who met all criteria were defined as the ‘ABC group’, and those who did not
meet all criteria were the ‘Non-ABC’ group.
2.1. Outcomes
In our analysis, we primarily assessed all-cause mortality and a composite outcome of
“ischemic stroke or systemic embolism, all-cause death and cardiovascular hospitalization’. The main
analysis is a comparison of the above-mentioned outcomes between AF patients with optimized,
integrated care holistic management (ABC group) and those without ABC pathway adherence
(non-ABC).
2.2. Statistical Analysis
Continuous variables were reported as mean ± standard deviation and evaluated by Student’s
t-test or Mann–Whitney, as appropriate. Categorical variables were expressed as percentages and
counts and compared using Pearson’s chi-square test or Fisher’s exact test, as necessary.
The major analyses included comparisons of the clinical outcomes between the two study groups:
ABC-group and non-ABC group, reflecting the ABC pathway compliance in the management of AF
patients. Secondary analyses evaluated the association between the components of ABC pathway,
when partially fulfilled, and clinical outcomes occurrence and also included analyses comparing the
non-ABC group with a group of partial compliance with ABC pathway (AB vs. BC vs. AC groups).
A logistic regression model was used to analyse the association between the groups considered
and the study outcomes. Odds ratios (ORs) and 95% confidence interval (CI) were used to express
the association. All multivariable regression models were adjusted for AF type, renal dysfunction,
dyslipidemia, use of aspirin, and major bleeding.
All tests were 2-tailed, and p-value < 0.05 was considered to be statistically significant. The analyses
were conducted using SPSS version 24 software package (SPSS Inc., Chicago, IL, USA).
3. Results
From 2043 patients in the Gulf SAFE registry, 22 (1.1%) were excluded from the analysis due to
missing data regarding CHA2DS2-VASc score. The cohort for the current study was comprised of 2021
patients, whose baseline characteristics are reported in Table 1.
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Table 1. Baseline characteristics of patients according to adherence to ABC pathway.
Characteristics All Patients(n = 2021)
ABC Group
(n = 168)
Non-ABC Group
(n = 1853) p Value
Demographics
Male gender, n (%) 1053 (52.1%) 91 (54.3%) 962 (51.9%) 0.58
Age, mean ± SD 56.74 ± 16.47 64.46 ± 11.92 56.04 ± 16.65 <0.001
Weight, mean ± SD 75.62 ± 18.29 78.98 ± 20.03 75.32 ± 18.11 <0.015
Height, mean ± SD 164.25 ± 9.40 163.14 ± 9.87 164.35 ± 9.35 0.12
BMI, mean ± SD 28.00 ± 6.38 29.63 ± 7.24 27.86 ± 6.28 0.001
Systolic BP, mmHg, mean ± SD 130.30 ± 26.46 121.6 ± 14.00 131.10 ± 27.18 <0.001
Diastolic BP mmHg, mean ± SD 79.03 ± 16.17 74.06 ± 10.25 79.50 ± 16.53 <0.001
Comorbidities, n (%)
Coronary artery disease, n (%) 573 (28.6%) 89 (53.3%) 484 (26.3%) <0.001
Hypertension, n (%) 1065 (52.7%) 117 (69.6%) 948 (51.2%) <0.001
Dyslipidemia, n (%) 677 (33.8%) 103 (61.2%) 574 (31.2%) <0.001
Heart failure, n (%) 557 (27.6%) 60 (35.7%) 497 (26.8%) 0.014
Ischemic stroke or TIA, n (%) 239 (11.8%) 19 (11.3%) 220 (11.9%) 0.83
Diabetes mellitus, n (%) 603 (29.8%) 86 (51.2%) 517 (27.9%) <0.001
Chronic kidney disease n (%) 122 (6.0%) 6 (3.6%) 116 (6.3%) 0.016
Smoking tobacco 461 (23.0%) 32 (19.2%) 429 (23.3%) 0.219
Stroke or bleeding risk scores
CHA2DS2-VASc, mean ± SD 2.34 ± 1.78 3.01 ± 1.53 2.28 ± 1.79 <0.001
HAS-BLED, mean ± SD 1.13 ± 1.065 1.33 ± 0.87 1.11 ± 1.08 0.008
Echocardiogram
Left atrium diameter (mm), n = 1444 44.36 ± 9.11 44.61 ± 7.03 44.34 ± 9.28 0.753
LVEF, %
n = 1490 51.23 ± 13.20 48.19 ± 14.44 51.51 ± 13.06 0.007
Medications, n (%) n = 1945 ABC group n = 168, non-ABC group n = 1777
ACEI 715 (36.8%) 113 (67.3%) 602 (33.9%) <0.001
ARB 279 (14.3%) 55 (32.7%) 224 (12.6%) <0.001
Aspirin 1058 (54.4%) 97 (57.7%) 961 (54.1%) 0.36
Beta-blocker 1133 (58.3% 119 (70.8%) 1114 (57.1%) 0.001
Verapamil or Diltiazem 164 (8.4%) 11 (6.5%) 153 (8.6%) 0.36
Other calcium channel blocker 160 (7.9%) 13 (7.7%) 147 (8.3%) 0.81
Clopidogrel 213 (11%) 22 (13.1%) 191 (10.7%) 0.35
Diuretics 949 (48.8%) 101 (60.01%) 848 (47.7%) 0.002
Digoxin 702 (36.1%) 55 (32.7%) 647 (36.4%) 0.34
Statin 938 (48.2%) 169 (97.0%) 775 (43.6%) <0.001
Other lipid-lowering drug 29 (1.5%) 7 (4.2%) 22 (1.2%) 0.003
Warfarin 1049 (51.9%) 155 (92.3%) 894 (50.3%) <0.001
Other anticoagulant 88 (4.5%) 13 (7.7%) 75 (4.2%) 0.036
Amiodarone 178 (9.2%) 27 (16.1%) 151(8.5%) 0.001
Flecainide 14 (0.7%) 1 (0, 6%) 13 (0.7%) 0.84
Propafenone 34 (1.7%) 1 (0, 6%) 33 (1.9%) 0.23
Sotalol 13 (0.7%) 2 (1.2%) 11 (0.6%) 0.38
Abbreviations: ACEI—angiotensin-converting-enzyme inhibitors, ARB—angiotensin receptor blockers, BMI—body
mass index, LVEF—left ventricular ejection fraction, TIA—transient ischemic attack.
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In general, 168 (8.3%) patients were managed adherent to the ABC pathway. In comparison to
the non-ABC adherent group, patients from ABC-adherent group were older (p < 0.001), had higher
BMI (p < 0.001), CHA2DS2-VASc (p < 0.001) and HAS-BLED scores (p = 0.008). Comparing to the
non-ABC adherent, the ABC-adherent group had lower systolic (p < 0.001) and diastolic blood pressure
(p < 0.001), as well as lower left ventricular ejection fraction (p = 0.007), acquired more comorbidities
and were treated with more drugs (Table 1). No relevant gender dominance was observed in either
group (male: 50.8% vs. 52.9%).
3.1. “ABC” Pathway Compliance
Detailed compliance of studied population to each of the ABC pathway steps is presented in
Table 2. Among the subjects studied, 1118 (54.7%) subjects were treated in line with “A” pathway step.
Classification of patients according to the ischemic stroke risk is shown in Figure 1. From the high
ischemic stroke risk group, 469 (33%) patients received OAC followed by single antiplatelet therapy
in 403 (28.3%), dual antiplatelet therapy 97 (6.8%), dual antithrombotic therapy 294 (20.7%) and 91
(6.4%) who were prescribed neither anticoagulation nor antiplatelet therapy. Detailed data about
anticoagulation management are reported in Table S1 available online.
Table 2. ABC pathway compliance.
Study Groups Compliance Non-Compliance
A 1118 (55.3%) 903 (44.7%)
B 1518 (75.1%) 503 (24.9%)
C 388 (19.2%) 1575 (77.9%)
ABC 168 (8.3%) 1853 (91.7)
Abbreviations: A—avoid stroke, B—better symptoms management, C—cardiovascular and other comorbidities.
The full ABC pathway compliance was highlighted in bold.
Figure 1. Relationship between events rates and odds ratio of clinical outcomes in 6 months follow-up.
Legend: Whiskers represent 95% CI; CI = Confidence Interval; OR = Odds Ratio.
“B” criterion was fulfilled in 1518 (75.1%) patients, who were optimally managed symptomatically
and hence reported no (or only mild) clinical symptoms (EHRA I-II).
AF was symptomatic significantly more often in patients with persistent/paroxysmal AF than in
those with paroxysmal AF form (25.2% vs. 15%, respectively, p < 0.001).
“C”-adherence, which means that the comorbidities were either well-controlled or treated
according to the international guidelines, was present in 388 (19.2%) (see Table S2).
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3.2. Clinical Outcomes
During a one-year follow-up (FU), 578 composite outcome events occurred, and 224 patients died.
Patients managed adherent to the ABC pathway had lower composite outcome and all-cause mortality
rates, both at 6 months and one-year FU: (i) 6 months FU (13.1% vs. 20%, p = 0.03 and 3% vs. 8%,
p = 0.018, respectively); and (ii) one-year FU (20.8% vs. 29.3%, p = 0.02 and 7.3% vs. 13.1%, p = 0.033,
respectively) (Figures 1 and 2).
Figure 2. Relationship between events rates and odds ratio of clinical outcomes in 1-year follow-up.
Legend: Whiskers represent 95% CI; CI = Confidence Interval; OR = Odds Ratio.
On multivariable regression analysis, ABC pathway compliance was independently associated
with reduced all-cause mortality risk at both 6-months (Odds ratio (OR) 0.31; 95% Confidence Interval
(CI) 0.13–0.77, p = 0.013) and one-year (OR 0.46; 95% CI 0.25–0.86, p = 0.015) FU in comparison to
non-ABC-compliant group.
An adjusted analysis showed also significant association with lower risk of the composite outcome
in ABC group versus non-ABC group in 6-months and one-year FU (OR 0.49; 95% CI 0.31–0.79,
p = 0.003 and OR 0.53; 95% CI 0.36–0.8, p = 0.002, respectively) (Table 3).
Table 3. Clinical outcomes at six-months and one-year follow-up.
Risk Factors
All-Cause Mortality Composite Outcome
6 Months 1 Year 6 Months 1 Year
OR
(95% CI) p Value
OR
(95% CI) p Value
OR
(95% CI) p Value
OR
(95% CI) p Value
AF type (paroxysmal vs.
persistent/permanent)
1.11
(0.92–1.33) 0.3
1.26
(1.07–1.48) 0.006
1.29
(1.13–1.46) <0.001
1.33
(1.19–1.49) <0.001
Renal dysfunction 3.04(1.86–4.97) <0.001
3.05
(1.91–4.89) <0.001
1.94
(1.30–2.92) 0.001
1.8
(1.22–2.65) 0.003
Dyslipidemia 1.20(0.83–1.73) 0.32
0.97
(0.71–1.33) 0.85
1.26
(0.99–1.62) 0.06
1.24
(0.99–1.54) 0.06
Use of aspirin 1.33(0.93–1.90) 0.12
1.45
(1.07–1.97) 0.018
1.41
(1.11–1.79) 0.006
1.42
(1.14–1.76) 0.001
Major bleeding 1.84(0.84–4.04) 0.13
1.74
(0.87–3.51) 0.12
2.13
(1.22–3.72) 0.008
3.09
(1.81–5.28) <0.001
ABC Compliance 0.31(0.13–0.77) 0.013
0.46
(0.25–0.86) 0.015
0.49
(0.31–0.79) 0.003
0.53
(0.36–0.80) 0.002
Abbreviations: CI—confidence interval, OR—odds ratio, TIA—transient ischemic attack.
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3.3. Number of Fulfilled ABC Criteria and Clinical Outcomes
Apart from the B criterion for the composite outcome (OR 0.57, 95% CI0.46–0.71), none of other
separate components were associated with significant difference in all-cause mortality or the composite
outcome. When we analysed the relationship between partial ABC compliance and the composite
outcome, AB (OR 0.75; 95% CI 0.61–0.92, p = 0.006) and BC (OR 0.68; 95% CI 0.50–0.92, p = 0.013)
criteria together were associated with reduced risk (Table 4).
Table 4. Relationship between ABC pathway components criteria and clinical outcomes.
Fulfilled Criteria
All-Cause Mortality Composite Outcome
1 Year 1 Year
OR (95% CI) p Value OR (95% CI) p Value
AB 0.78 (0.58–1.06) 0.12 0.75 (0.61–0.92) 0.006
AC 0.95 (0.62–1.46) 0.83 1.0 (0.74–1.36) 0.99
BC 0.73 (0.47–1.13) 0.16 0.68 (0.50–0.92) 0.013
Abbreviations: CI—confidence interval, OR—odds ratio.
Neither one nor two fulfilled criteria were significantly associated with reduced risk of all-cause
death in one-year FU. Only full ABC pathway compliance, i.e., all 3 criteria were fulfilled at the
same time, was independently associated with a significantly reduced risk of all-cause death and
the composite outcome at both 6-months (OR 0.31; 95% CI 0.13–0.77, p = 0.013, and OR 0.46; 95% CI
0.25–0.86, p = 0.015, respectively); as well as at 1 year (OR 0.49; 95% CI 0.31–0.79, p = 0.003 and OR 0.53;
95% CI 0.36–0.8, p = 0.002, respectively).
4. Discussion
This international cohort study from the Middle East was based on a real-world observational
registry of AF patients aimed to assess the adherence of AF management according to the ABC pathway
and its outcomes. The analysis demonstrated that the vast majority of patients were not managed
optimally in accordance with the ABC pathway. Second, ABC integrated care was associated with
a reduced risk of all-cause death and the composite outcome in comparison to non-ABC complaint
group. Third, the impact of ABC pathway adherence on all-cause mortality and composite outcome
reduction was independent of FU duration.
The beneficial effect coming from integrated care and holistic approach to AF treatment is
documented in many randomized control trials and real-world evidence studies [14,15]. The importance
of this comprehensive treatment was also underlined by the 2016 European Society of Cardiology
guidelines [8]. The ABC integrated pathway meets these requirements and was proposed to simplify
treatment regimens and provide practical and simple steps to guarantee holistic care for AF patients in
everyday clinical practice [4]. The ABC pathway has also been incorporated into the regional primary
care guidelines for AF management [12]. According to these studies, treatment adherent with the
integrated care (ABC group) was associated with a significant reduction in all-cause mortality as well
as the composite outcome including ischemic stroke, major bleeding, cardiovascular death, myocardial
infarction and rate of total hospitalizations in comparison to non-ABC compliant group [10–12]. Our
findings are in line with the above-mentioned studies showing reduced risks of all-cause mortality and
composite outcome in the ABC group compared to non-ABC.
Moreover, the association between ABC pathway compliance and the reduced risk of the primary
endpoints (all-cause death and composite outcomes) and was independent of other common risk
factors and constant in 6-months or 1-year FU (Table 3). This is all the more important as AF is a
disease that usually affects the elderly, who acquire several comorbidities over time [16–18].
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In contrast to the previous studies concerning ABC pathway adherence in various populations,
the current study was noticeably younger and had lower burden of comorbidities. Unlike prior studies,
the ABC-adherent group in our analysis had a significantly higher ischemic stroke and bleeding
risk (p < 0.005) [11,12,19]. Nonetheless, even in this specific population, adherence with the ABC
population was strongly associated with reduced mortality and the composite outcome.
The current analysis also exposed insufficient compliance with the individual steps of the ABC
integrated care in the Middle East region. Overall, the number of AF patients, fulfilling the ABC
pathway criteria was eleven-times lower than the number of people who were not compliant with this
management pathway (8.3% vs. 91.7%, respectively). These results obtained were more favourable than
those from other research studies conducted in Asian and European populations, where the compliance
with ABC pathway was fulfilled in 15.5%; 22.4% and 7.0%, respectively [11,12,19]. Although these
retrospective studies varied slightly in terms of ABC pathway definition, the size of the analysed
cohorts and available confounders, the overall message of integrated care is preserved, and all studies
consistently reported the efficacy and superiority of ABC pathway compliance in AF patients.
Strengths and Limitations
This is the first, multinational study evaluating the AF treatment adherence with the ABC
integrated care pathway and its influence on relevant clinical outcomes in the Middle East population.
The database is based on a large number of consecutive patients from various medical centres that met
precisely defined criteria, which enhances the reliability of the analysis results.
Nevertheless, there are also some limitations, which should be considered. This was an
observational study, some analyses might be underpowered, and some bias and deficiencies of
assessment may have occurred. The BP classification was based on an average of at least 3 measurements
during the hospital admission and might not reflect the actual BP targets for all individuals. Due to
the retrospective nature of the study, we were not able to interfere in the treatment regimen that
has changed over time. The Gulf-SAFE dataset was created in 2009 and 2010 when Non-vitamin-K
Antagonist Oral Anticoagulants (NOAC) use were hardly used, therefore, the vast majority of patients
receiving OAC in the Gulf SAFE registry were using VKA. Furthermore, the guidelines have changed
over that time period what might have altered AF management in the Middle East and influenced the
results. Nevertheless, most of the analyses were based on fundamental AF management principles
which have been in textbooks for the last decade or more, that is, stroke prevention, manage symptoms
with rate or rhythm control, and the optimization of comorbidities. Finally, our registry was conducted
in a broad spectrum of clinical settings, in six Gulf region countries—but we would be unable to
perform our analysis by individual country. Moreover, because of limited data availability, we might
have missed many confounders that could impact the final results.
5. Conclusions
In conclusion, integrated ABC pathway adherent care resulted in the reduced composite outcome
and all-cause mortality in AF patients from Middle East, highlighting the necessity of promoting
comprehensive holistic and integrated care management of AF.
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comorbidities according to the current guidelines.
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